UNSPSC 51263147: Atenolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H22N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DI0UT7U1Q, chemically known as benzeneacetamide, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, monohydrochloride but more generally known as atenolol hydrochloride, which bears US NIH Compound Identifier 119274. European Medicines Agency schedules Atenolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00615MIG.

Most nations, for tariff and trade purposes, schedule atenolol hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, ATENOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)NCC(COC1CCC(CC1)CC(=O)N)O.CL.

UNSPSC 51263147 Atenolol hydrochloride is a Commodity code nominally designating a specific beta-blocker pharmaceutical, but recent state and local activity under this code shows substantial mismatch with the category name. The Seminole County, Florida IFB and the Texas Health and Human Services Commission RFI both posted in 2026 involve broader pharmacy procurement and pharmaceutical supply chain initiatives — naloxone kits, drug deactivation systems, and direct-to-manufacturer prescription programs — rather than atenolol-specific procurement. State and local purchasing offices appear to be using this code as a catch-all for pharmaceutical-related goods and services beyond the single drug product the code nominally describes. Issuing bodies include county health departments (Seminole County) and state health and human services agencies (Texas HHS Commission), reflecting a mix of tactical operational procurement and strategic program-design exploration.

The geographic concentration evident in recent postings centers on Florida and Texas, with no additional jurisdictions represented in the available opportunities. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: date discrepancy in source), specifying quarterly deliveries to the Seminole County Community Health Building with shipping costs included in vendor proposals and an initial two-year term plus one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, requesting vendor capabilities and market intelligence on direct-to-manufacturer prescription programs that bypass traditional pharmacy benefit managers and group purchasing organizations. The RFI serves as exploratory research prior to formal RFP issuance and does not specify budget ranges, set-asides, or award timelines. The code shows limited and tangentially related recent activity; vendors pursuing pharmaceutical supply work should verify actual code assignment with issuing procurement offices before bid investment.